Pfizer’s Xeljanz Could See Narrower Label And New REMS Due To CV And Malignancy Risks
Executive Summary
The US FDA will ponder its regulatory options now that final data are in from a long-term postmarketing study showing tofacitinib is associated with a higher rate of major adverse cardiovascular events and malignancies compared with TNF-inhibitors.